ADHD Medication Associated with Reduced Risk for Motor Vehicle Crashes

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 10, 2017

Media Advisory: To contact study corresponding author Zheng Chang, Ph.D., M.Sc., email zheng.chang@ki.se.

Related material: The commentary, “Distracted Driving with Attention-Deficit/Hyperactivity Disorder,” by Vishal Madaan, M.D, and Daniel J. Cox, Ph.D., of the University of Virginia Health System, Charlottesville, also is available on the For The Media website.

To place an electronic embedded link to this study in your story Link will be live at the embargo time: http://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2017.0659

 

JAMA Psychiatry

In a study of more than 2.3 million patients in the United States with attention-deficit/hyperactivity disorder (ADHD), rates of motor vehicle crashes (MVCs) were lower when they had received their medication, according to a new article published by JAMA Psychiatry.

About 1.25 million people worldwide die annually because of MVCs. ADHD is a prevalent neurodevelopmental disorder with symptoms that include poor sustained attention, impaired impulse control and hyperactivity. ADHD affects 5 percent to 7 percent of children and adolescent and for many people it persists into adulthood. Prior studies have suggested people with ADHD are more likely to experience MVCs. Pharmacotherapy is a first-line treatment for the condition and rates of ADHD medication prescribing have increased over the last decade in the United States and in other countries.

Zheng Chang, Ph.D., M.Sc., of the Karolinska Institutet, Stockholm, Sweden, and coauthors identified more than 2.3 million U.S. patients with ADHD between 2005 and 2014 from commercial health insurance claims and identified emergency department visits for MVCs. Analyses compared the risk of MVCs during months when patients received their medication with the risk of MVCs during months when they did not.

Among the more than 2.3 million patients with ADHD (average age 32.5), 83.9 percent (more than 1.9 million) received at least one prescription for ADHD medication during the follow-up. There were 11,224 patients (0.5 percent) who had at least one emergency department visit for an MVC.

Patients with ADHD had a higher risk of an MVC than a control group of people who didn’t have ADHD or ADHD medication use. The use of medication in patients with ADHD was associated with reduced risk for MVC in both male and female patients, according to the results.

“These findings call attention to a prevalent and preventable cause of mortality and morbidity among patients with ADHD. If replicated, our results should be considered along with other potential benefits and harms associated with ADHD medication use,” the article concludes.

Limitations of the study include that it cannot prove causality because it is an observational study. Medication use also was measured by monthly filled prescriptions. Also, the study used emergency department visits due to MVCs as its main outcome so some MVCs that did not require medical services (for example less severe crashes or some fatal ones) were not included in the study.

For more details and to read the full study, please visit the For The Media website.

(doi:10.1001/ jamapsychiatry.2017.0659.)

Editor’s Note: The article contains conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

 

# #  #

 

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.